Quote | Imugene Ltd (OTCMKTS:IUGNF)
Last: | $0.0528 |
---|---|
Change Percent: | 13.33% |
Open: | $0.0455 |
Close: | $0.0528 |
High: | $0.0528 |
Low: | $0.0455 |
Volume: | 15,286 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Imugene Ltd (OTCMKTS:IUGNF)
(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) complia...
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieve...
Message Board Posts | Imugene Ltd (OTCMKTS:IUGNF)
Subject | By | Source | When |
---|---|---|---|
Great news, | skitahoe | investorshub | 06/27/2022 5:57:09 AM |
Very good news - https://finance.yahoo.com/news/city-hope-imugene-announce-first | Amatuer17 | investorshub | 05/18/2022 8:25:16 PM |
Imugene granted patent in Japan! | soseano | investorshub | 09/21/2021 11:47:42 PM |
Thanks, it doesn't seem to want to accept | skitahoe | investorshub | 09/18/2021 11:03:11 PM |
Hi Skitahoe, there is a fountain of knowledge | Jason d Schwarz | investorshub | 09/18/2021 9:14:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Imugene Ltd Company Name:
IUGNF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) complia...
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieve...
(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intr...